REG - BioPharma Credit PLC - UPDATE ON INVESTMENT PORTFOLIO

Biopharma CreditAnnouncement

Today 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260318:nRSR1745Xa&default-theme=true

RNS Number : 1745X  BioPharma Credit PLC  18 March 2026

18 March 2026

 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

UPDATE ON INVESTMENT PORTFOLIO

 

New Investment of US$50 Million and Paratek Repayment

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investment
trust, notes the announcement released by Paratek Pharmaceuticals, Inc.
("Paratek") on 18 March 2026 regarding the completion of its combination with
Radius Health, Inc. (the "Transaction").

 

Paratek - New US$50 Million Investment

 

As noted by Paratek, the Transaction was financed in part with debt financing
from funds managed by Blackstone; Sixth Street; Oaktree Capital Management,
L.P.; Silver Point Capital; and Pharmakon Advisors, LP (the "New Paratek
Financing").  The Company is pleased to announce that it, through its fully
owned subsidiary, and BioPharma Credit Investments V (Master) LP
("BioPharma-V"), each funded US$50 million in the New Paratek Financing.  The
Company's new investment as part of the Transaction replaced a previous debt
financing in which the Company had a US$25 million investment, which was
repaid in its entirety by the New Paratek Financing.  Since Paratek is a
privately held company, further details about the New Debt Financing are not
publicly available, but the terms of the loan are generally comparable with
the Company's other investments.

Paratek is a privately held specialty pharmaceutical platform company with a
portfolio of diverse, innovative medicines well positioned for long-term
growth.  Paratek's product, NUZYRA (omadacycline), is a once-daily oral and
intravenous antibiotic indicated for adults with community-acquired bacterial
pneumonia (CABP) and acute bacterial skin and skin structure infections
(ABSSSI).  In connection with the Transaction, Paratek added the osteoporosis
therapy TYMLOS (abaloparatide) to its growing commercial portfolio of
differentiated specialty medicines. Paratek became a private company in 2023
when it was acquired by B-FLEXION Life Sciences and Novo Holdings. The
Transaction brings together two complementary organizations backed by
B‑FLEXION Life Sciences, and further advances Paratek's growth strategy of
building a pharmaceutical platform in high-need, targeted therapeutic areas.
The combined company is expected to generate nearly $1 billion in revenue in
2026, reflecting the scale and breadth of Paratek's platform.

Paratek - Prepayment

 

In connection with the closing of the New Paratek Financing, the previous
US$275 million senior secured facility at Paratek was repaid in full.  The
Company had previously announced on 22 May 2025 the entering into of the
US$275 million senior secured facility, of which each of the Company and
BioPharma-V funded US$25 million at closing.  The Company received a payment
of US$27 million, comprised of US$25 million in returned principal and US$2
million of prepayment fees and accrued interest.

 

Enquiries:

 

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

 

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCJPMBTMTTBBAF



            Copyright 2019 Regulatory News Service, all rights reserved